Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.53 |
| ▸ | CNR1 | P21554 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5462921 | 0.90 | SMN1; SMN2 (0.55) | CNR1LMNASMN1; SMN2CNR2P2RX7 | |
| SCHEMBL5452999 | 0.88 | KMT2A (0.52) | L3MBTL1CNR1CNR2POLBP2RX7 | |
| SCHEMBL14411259 | 0.88 | SMN1; SMN2 (0.55) | CNR1SMN1; SMN2CNR2P2RX7PLK1 | |
| SCHEMBL5455250 | 0.87 | CNR2 (0.48) | CNR1SMN1; SMN2CNR2P2RX7PLK1 | |
| SCHEMBL5455285 | 0.86 | KDM4E (0.52) | CNR1CNR2P2RX7PLK1 | |
| SCHEMBL5452278 | 0.83 | CNR1 (0.59) | L3MBTL1TSHRNR4A2CNR1GAA | |
| SCHEMBL5456168 | 0.83 | L3MBTL1 (0.61) | L3MBTL1TSHRNR4A2CNR1GAA | |
| SCHEMBL5453757 | 0.82 | NR4A2 (0.54) | L3MBTL1TSHRNR4A2CNR1GAA | |
| SCHEMBL5449197 | 0.81 | NR4A2 (0.57) | L3MBTL1TSHRNR4A2CNR1GAA | |
| SCHEMBL5450991 | 0.81 | NR4A2 (0.60) | L3MBTL1TSHRNR4A2CNR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | L3MBTL1 4494/4885TSHR 87/4885NR4A2 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.